FDA Approves Teva's Digital Asthma Inhaler With Built-In Sensors
2018年12月22日 - 6:39AM
Dow Jones News
By Maria Armental
A digital version of Teva Pharmaceutical Industries Ltd.'s
(TEVA, TEVA.TV) ProAir asthma inhaler has been approved for sale by
the U.S. Food and Drug Administration, the company said Friday.
The ProAir Digihaler, which releases about 117 mcg of albuterol
sulfate and is intended for those aged 4 and older, has built-in
sensors to detect when the inhaler is used and measure inspiratory
flow. The sensors connect to a mobile application, Teva said.
Teva said it will introduce the product on a limited basis in
2019 through some "early experience" programs in partnership with
healthcare systems and plans to launch it nationally in 2020.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
December 21, 2018 16:24 ET (21:24 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2024 まで 8 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 8 2023 まで 8 2024
